Observational studyBMJ open2022
Real-life impact of uncontrolled severe asthma on mortality and healthcare use in adolescents and adults: findings from the retrospective, observational RESONANCE study in France.
Observational study in BMJ open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- A bibliometric and scientific knowledge map study of the drug therapies for asthma-related study from 1982 to 2021.Frontiers in pharmacology · 2022Pooled it
- Long-term safety of mepolizumab for up to ∼10 years in patients with severe asthma: open-label extension study.Annals of medicine · 2024Trial
- Baseline Characteristics of Patients with Asthma Initiating Dupilumab in a Real-World Setting: The REVEAL Registry.Advances in therapy · 2026Observational
- Documented Nicotine, Cannabis, and Co-Use Are Associated With More Intensive Emergency Department Care for Adolescent Asthma Exacerbations.Journal of the American College of Emergency Physicians open · 2026Article
- Real-World Adherence to Asthma and COPD Medications in Belgium: A Nationwide Analysis of Determinants Using Dispensing Data and Mixed-Effects Modeling.Healthcare (Basel, Switzerland) · 2026Article
- Cost-effectiveness analysis of mepolizumab among patients with severe asthma from the Chinese societal perspective.PloS one · 2026Article
- Article
- Mortality Among Adults with Subspecialist-Treated Severe Asthma: A Descriptive Analysis from the Observational CHRONICLE Study.Journal of asthma and allergy · 2026Article
- Unravelling the exposome of severe exacerbations of obstructive respiratory diseases in France.BMJ open respiratory research · 2025Article
- Asthma Control and Its Related Trigger Factors in Primary Health Care in the Kingdom of Bahrain.Cureus · 2025Article
- Achieving remission in severe asthma.Chinese medical journal pulmonary and critical care medicine · 2025Review
- A cost-effectiveness analysis comparing single-inhaler extrafine beclomethasone/formoterol/glycopyrronium bromide against other SITTs in adult patients with uncontrolled asthma in England.Health economics review · 2025Article
- Defense mechanisms in immune-mediated diseases: a cross-sectional study focusing on Severe Allergic Asthma and Hymenoptera Venom Anaphylaxis patients.Frontiers in psychology · 2025Article
- Real-World Effectiveness of Mepolizumab in Severe Asthma: Results from the Multi-country, Self-controlled Nucala Effectiveness Study (NEST).Advances in therapy · 2024Observational
- Impact of CYP3A5 Polymorphisms on Pediatric Asthma Outcomes.International journal of molecular sciences · 2024Article
- A Roadmap for Using Causal Inference and Machine Learning to Personalize Asthma Medication Selection.JMIR medical informatics · 2024Article
- Patient education needs in severe asthma, a pilot study.BMC pulmonary medicine · 2024Article
- Health-related quality of life in severe hypersensitivity reactions: focus on severe allergic asthma and hymenoptera venom anaphylaxis-a cross-sectional study.Frontiers in psychology · 2024Article
- Healthcare Resource Utilisation of Severe Uncontrolled T2low and Non-T2low Asthma in Finland During 2018-2021.Journal of asthma and allergy · 2024Article
- Current Approaches in the Multimodal Management of Asthma in Adolescents-From Pharmacology to Personalized Therapy.Biomedicines · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo characterise uncontrolled severe asthma and compare the disease burden with the general and asthmatic populations.
designRetrospective observational study using a national sample of a French healthcare database (Echantillon Généraliste des Bénéficiaires (EGB)).
settingThe EGB, an anonymised permanent sample of health insurance databases, representing 1/97th of the French population.
participantsPatients (≥12 years) were selected in year 2014 and followed 2 years. A cohort of patients with uncontrolled severe asthma was defined using an algorithm based on peer-reviewed literature and Global Initiative for Asthma recommendations. Index date was the occurrence of the first marker of uncontrolled asthma. This cohort was matched with two control cohorts, general population and asthmatic controls, on baseline characteristics. MAIN OUTCOMES MEASURES: Mortality, healthcare use and associated costs were studied in the 2 years of follow-up.
resultsAmong 467 716 individuals in the EGB, 16 588 patients with asthma were identified, including 739 (4.5%) with uncontrolled severe disease. The survival probability at 2 years for patients with uncontrolled severe asthma (92.0%) was lower than in the general population cohort (96.6%; relative risk of death: 2.35; 95% CI: 1.70 to 3.29; p<0.0001) and tended to be lower than in the control asthmatic cohort (94.3%; p=0.07). Emergency department visits and hospitalisations were higher in patients with uncontrolled severe asthma than in the general population (64.7% vs 34.9%; p<0.0001) and asthmatic controls (64.7% vs 55.2%; p=0.0002). Other components of healthcare use (medical and paramedical visits, medications) were increased in patients with uncontrolled severe asthma compared with control populations. These increases translated into higher costs (p<0.0001 for both comparisons).
conclusionsThis study demonstrates the huge burden of uncontrolled severe asthma in terms of mortality, morbidity and healthcare resource consumption compared with other patients with asthma and with the general population and emphasises the importance of appropriate management in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.